BRCA1 and BRCA2-Associated HBOC Syndrome Panel, Sequencing and Deletion/Duplication
Germline analysis of the BRCA1 and BRCA2 genes in individuals with a suspected diagnosis of hereditary breast and ovarian cancer (HBOC) syndrome. When a relative has a previously identified pathogenic sequence variant, see Familial Mutation, Targeted Sequencing (2001961).
Massively Parallel Sequencing/Multiplex Ligation-dependent Probe Amplification
New York DOH Approval Status
Lavender (EDTA) or Yellow (ACD Solution A or B).
Transport 3 mL whole blood. (Min: 2 mL)
Serum or plasma; grossly hemolyzed or frozen specimens
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
Laboratory Developed Test (LDT)
Genes tested: BRCA1 (NM_007294), BRCA2 (NM_000059)
|Component Test Code*||Component Chart Name||LOINC|
- Hereditary Breast
- Ovarian Cancer